Pfizer recruiting Phase 4 rimegepant safety study in India for triptan-refractory migraine patients
Pfizer is enrolling about 60 adults in India for an open-label study of rimegepant 75 mg ODT in migraine patients who did not respond to, could not tolerate, or cannot use triptans.
This week's only registry activity for Pfizer is a new Phase 4 trial in India.
- Pfizer is recruiting for an open-label multicenter Phase 4 study evaluating the safety and tolerability of rimegepant 75 mg orally disintegrating tablet for the acute treatment of migraine, with or without aura, in adult patients in India who have had an insufficient response, intolerance, or contraindication to triptans.1 The study will enroll approximately 60 participants,1 and its primary endpoints are incidence of treatment-emergent adverse events and incidence of serious adverse events.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.